细胞生物免疫治疗联合化疗对非小细胞肺癌患者凋亡相关基因和免疫功能的影响  

Effect of cellular immunotherapy combined with chemotherapy on apoptosis-related genes and immune function in patients with non-small cell lung cancer

作　　者：张伟萍 应海峰 贺茹依 徐有祖 Zhang Weiping;Ying Haifeng;He Ruyi;Xu Youzu(Department of Geriatrics,Taizhou Hospital of Zhejiang Province,Wenzhou Medical University,Taizhou 317000,Zhejiang Province,China;Department of Anesthesia,Taizhou Hospital of Zhejiang Province,Wenzhou Medical University,Taizhou 317000,Zhejiang Province,China;Respiratory Department,Taizhou Hospital of Zhejiang Province,Wenzhou Medical University,Taizhou 317000,Zhejiang Province,China)

机构地区：[1]温州医科大学附属浙江省台州医院老年医学科,317000 [2]温州医科大学附属浙江省台州医院麻醉科,317000 [3]温州医科大学附属浙江省台州医院呼吸科,317000

出　　处：《中国基层医药》2021年第6期806-810,共5页Chinese Journal of Primary Medicine and Pharmacy

基　　金：浙江省医药卫生科技计划项目(2019KY771)。

摘　　要：目的:探讨树突状细胞诱导的杀伤细胞(DC-CIK)生物免疫治疗联合化疗对中晚期非小细胞肺癌患者凋亡相关基因和免疫功能的影响。方法:选取温州医科大学附属浙江省台州医院2018年2月至2019年5月收治的中晚期非小细胞肺癌患者100例,采用随机数字表法分为对照组、观察组各50例。两组患者均给予培美曲塞联合顺铂化疗,观察组加用DC-CIK细胞生物免疫治疗。观察两组凋亡相关基因[原发性小头畸形基因(MCPH1)、毛细血管扩张性共济失调症突变基因(ATM)、毛细血管扩张性共济失调症突变基因Rad3相关蛋白(ATR)、转录因子21(TCF21)]、免疫功能的变化,并评定临床疗效。结果:治疗后,观察组MCPH1、ATM、ATR、TCF21分别为(301.11±41.12)、(239.98±30.15)、(270.01±36.01)、(270.01±34.02),均显著高于对照组的(101.32±15.32)、(103.00±13.97)、(101.12±14.90)、(100.20±14.99)(t=32.194、29.149、30.644、32.299,均P<0.001);观察组Th1细胞为(29.00±3.41)%,显著高于对照组的(22.61±3.22)%(t=9.634,P<0.001);观察组Th17细胞、Th2细胞、CD+4CD+25Treg细胞分别为(0.89±0.10)%、(12.01±1.36)%、(11.02±1.92)%,均显著低于对照组的(1.70±0.20)%、(17.61±2.20)%、(18.70±2.40)%(t=25.614、15.310、17.670,均P<0.001);观察组总有效率为52.0%(26/50),显著高于对照组的30.0%(15/50)(χ2=5.002,P<0.05)。结论:DC-CIK细胞生物免疫治疗联合化疗,能诱导细胞凋亡,调节免疫功能,其疗效显著优于单纯化疗。Objective To investigate the effect of immunotherapy with dendritic cells and cytokine-induced killer cells combined with chemotherapy on apoptosis-related genes and immune function in patients with middle-and advanced-stage non-small cell lung cancer.Methods A total of 100 patients with middle-and advanced-stage non-small cell lung cancer who received treatment in Taizhou Hospital of Zhejiang Province,Wenzhou Medical University,China from February 2018 to May 2019 were included in this study.They were randomly divided into control and observation groups(n=50/group).The two groups were given chemotherapy with pemetrexed and cisplatin.The observation group was given immunotherapy with dendritic cells and cytokine-induced killer cells based on chemotherapy with pemetrexed and cisplatin.Changes in apoptosis-related genes[primary autosomal recessive microcephaly gene(MCPH1),ataxia-telangiectasia mutated(ATM),ataxia telangiectasia mutated and Rad3 related(ATR),transcription factor 21(TCF21)]and immune function were monitored.Clinical efficacy of immunotherapy with dendritic cells and cytokine-induced killer cells combined with chemotherapy with pemetrexed and cisplatin in the treatment middle-and advanced-stage non-small cell lung cancer was assessed.Results After treatment,expression of MCPH1,ATM,ATR and TCF21 in the observation group was 301.11±41.12,239.98±30.15,270.01±36.01,270.01±34.02,respectively,which was significantly higher than that in the control group[101.32±15.32,103.00±13.97,101.12±14.90,100.20±14.99,t=32.194,29.149,30.644,32.299,all P<0.001].The proportion of the number of Th1-positive cells in the number of CD+4 T cells in the observation group was significantly higher than that in the control group[(29.00±3.41)%vs.(22.61±3.22)%,t=9.634,P<0.001].The proportion of the number of Th17-,Th2 and CD+4CD+25Treg-positive cells in the number of CD+4 T cells in the observation group were(0.89±0.10)%,(12.01±1.36)%,(11.02±1.92)%,respectively,which were significantly lower than those in the control gr

关 键 词：癌 非小细胞肺 细胞生物学 免疫疗法 过继 细胞因子诱导杀伤细胞 药物疗法 凋亡调节蛋白质类 免疫调节 

分 类 号：R734.2[医药卫生—肿瘤]